Powerful therapeutics to reprogram pathological gene networks
First company harnessing network science, single-cell omics, and generative AI to create drugs that restore healthy gene regulation by reprogramming transcription factor networks to produce safe, deep and consistent therapeutic effects where other drugs cannot
A Unique therapeutic strategy
Reprogramming diseased networks of transcription factors (TF) to achieve therapeutic effects not attainable with traditional pharmacological strategies
Transcription factor network of a normal neuron from the brain part of the brain called the striatum. Transcription factors operate under normal rules and the neuron is healthy
TF networks control transcriptomes and cell status through structured and hierarchical networks. Most diseases are caused by a loss of structure and hierarchy of those networks.
Core Bio REPROGRAM AI platform identifies single TFs or groups of TFs capable of reprogramming diseased networks to engage entire transcriptomes toward therapeutic effects, overcoming the limitations of strategies based on single pathways to achieve broad and consistent effects for individual patients and across patient populations
Transcription factor network of patient with Huntington's disease in the same neuron of the striatum. Its abnormal structure and hierarchy enables pathological gene expression driving the disease
Core Bio develops a drug, COR800, to reprogram HD networks toward a normal status to stop the disease
We discovered the same pathologic network mechanism is at play across diseases - whether auto-immune, cancer, muscular dystrophy, cardiac, or fibrotic - and we develop network modifying drugs at scale against those disease
Core Bio develops a drug, COR800, to reprogram HD networks toward a normal status to stop the disease
We discovered the same pathologic network mechanism is at play across diseases - whether auto-immune, cancer, muscular dystrophy, cardiac, or fibrotic - and we develop network modifying drugs at scale against those disease
Innovative Drugs
Oral DNABBlocking super dominant transcription factor with first in class oral DNA binding molecules (DNAB)
Unique capabilities to target transcription factors (TF), the protein that regulate the expression of ALL GENES
HyperOligosBlocking multiple transcription factors with a single hyperOligo when one target is not enough